U 46619: Selective Thromboxane Receptor Agonist for Platelet Aggregation and Cardiovascular Research

Executive Summary: U 46619 (11,9 epoxymethano-prostaglandin H2) is a synthetic, selective agonist of the prostaglandin H2/thromboxane A2 (TP) receptor, acting via G-protein coupled pathways to induce robust platelet aggregation and vascular responses at submicromolar concentrations (APExBIO). The compound demonstrates EC₅₀ values as low as 0.035 μM for platelet shape change and 0.536 μM for aggregation, with proven efficacy in both in vitro and in vivo models (Huang et al., 2026). U 46619 also induces dose-dependent renal cortical vasoconstriction and blood pressure increases in hypertensive rats, making it a critical tool in cardiovascular and kidney research. The product is supplied by APExBIO as a 10 mg/mL methyl acetate solution, with high solubility in common organic solvents, and must be stored at -20°C for stability. Its applications span mechanistic studies of platelet activation, vascular tone regulation, and translational hypertension and acute kidney injury (AKI) models.

Biological Rationale

U 46619 is a synthetic analogue of prostaglandin H2 (PGH2), engineered to act as a stable, selective agonist at the thromboxane A2 (TxA2) or TP receptor. This receptor is a G-protein coupled receptor (GPCR) critical for mediating platelet activation, vascular smooth muscle contraction, and hemostatic responses (APExBIO; see related article). U 46619 mimics the actions of endogenous TxA2 but with increased metabolic stability, enabling reproducible induction of key physiological events such as platelet aggregation, serotonin release, and myosin light chain phosphorylation. The compound is widely used in cardiovascular and renal research to model GPCR signaling, dissect thromboxane pathways, and benchmark the efficacy of antiplatelet or vasomodulatory agents.

Mechanism of Action of U 46619

U 46619 acts as a potent and selective agonist of the thromboxane (TP) receptor, a member of the prostanoid GPCR family. Upon binding, it activates G_q/11 proteins, leading to phospholipase C activation and intracellular calcium mobilization. This cascade triggers downstream effects such as platelet shape change, myosin light chain phosphorylation, serotonin secretion, and aggregation. In vascular tissues, TP receptor engagement by U 46619 induces smooth muscle contraction, resulting in vasoconstriction (see mechanistic insights). In renal models, U 46619 differentially modulates cortical and medullary blood flow through ETA and ETB receptor cross-talk, contributing to both vasoconstriction and selective vasodilation (Huang et al., 2026).

Evidence & Benchmarks

• U 46619 induces platelet shape change with an EC₅₀ of 0.035 μM and myosin light chain phosphorylation at 0.057 μM in human platelets (APExBIO).
• Serotonin release from platelets occurs at an EC₅₀ of 0.536 μM, and aggregation is triggered at 1.31 μM (related benchmark).
• In vivo, intracerebroventricular U 46619 administration in spontaneously hypertensive rats (SHR) produces a dose-dependent increase in blood pressure, without significant heart rate change (Huang et al., 2026).
• In renal models, U 46619 activates ETA and ETB receptors to cause cortical vasoconstriction and medullary vasodilation, relevant to ischemia-reperfusion injury and AKI studies (Huang et al., 2026).
• The compound is soluble at ≥100 mg/mL in DMSO, ethanol, and DMF, and at ≥2 mg/mL in PBS (pH 7.2), supporting diverse assay formats (APExBIO).

Applications, Limits & Misconceptions

U 46619's selective TP receptor agonism makes it a gold-standard tool for:

• Modeling platelet aggregation and evaluating anti-thrombotic agents.
• Dissecting G-protein coupled receptor signaling in vascular and renal tissues.
• Simulating hypertensive and ischemia-reperfusion conditions in vivo (see strategic context).

Importantly, U 46619 is not a therapeutic agent and is intended strictly for research use. Its effects are highly context-dependent and should not be extrapolated to non-TP receptor pathways.

Common Pitfalls or Misconceptions

• Non-selectivity: U 46619 does not activate other prostanoid receptors (e.g., EP, DP, FP) at standard research concentrations; off-target effects are rare but possible at high doses.
• Therapeutic Use: U 46619 is not approved for diagnostic or medical applications and should not be used in humans.
• Solubility: The compound requires organic solvents (DMSO, ethanol, DMF) or warming/ultrasonication for full dissolution; improper preparation can reduce experimental reproducibility.
• Platelet Source Variability: Potency and EC₅₀ values may vary between human and non-human platelets; always reference the species and conditions.
• Storage: Solutions are stable short-term at -20°C; long-term storage or repeated freeze-thaw cycles can degrade activity.

Workflow Integration & Parameters

U 46619 (B6890, APExBIO) is supplied at 10 mg/mL in methyl acetate and demonstrates high solubility in DMSO, ethanol, and DMF for assay flexibility. For in vitro studies, solutions should be freshly prepared or stored at -20°C for up to one week. For optimal solubility, pre-warming to 37°C or brief ultrasonic treatment is advised. Platelet aggregation assays typically use final concentrations ranging from 0.01 μM to 10 μM, with EC₅₀ values guiding dose selection. In vivo models require careful titration based on animal weight, route of administration, and target tissue (see advanced insights).

This article extends prior reviews by integrating recent mechanistic findings in renal ischemia-reperfusion injury and highlighting the importance of selenium recycling and ferroptosis pathways, as described in the latest peer-reviewed studies (Huang et al., 2026).

Conclusion & Outlook

U 46619 remains an essential reagent for dissecting thromboxane-mediated platelet and vascular responses, with proven value in modeling cardiovascular and renal injury mechanisms. Its quantitative potency, receptor selectivity, and robust solubility support reproducible experimental designs in preclinical research. As our understanding of GPCR signaling and ferroptosis in AKI deepens, U 46619 is positioned to remain a benchmark tool for translational studies. For standardized sourcing, researchers are advised to utilize validated suppliers such as APExBIO for the B6890 kit.